Francis Mhimbira

In the News

Laboratory technician is required

Ifakara Health Institute (IHI) is looking for a laboratory technician to work with NC. TB – DAR project in Bagamoyo.The candidate will perform routine experimental laboratory test- mainly in the …

Field Supervisors required

IHI is looking for Field supervisors to fill a vacant positions in a new project on “Calcium supplementation in pregnant women” The Field supervisor will supervise all field activities at …

Recent Projects

Sustainable, Healthy, Learning Cities and Neighbourhoods

The Sustainable, Healthy, Learning Cities and Neighbourhoods is an exciting project in which IHI works with a consortium of partners from Asia and Africa to 1) develop capacity for improved …

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Francis Mhimbira

Research Scientist and Head of Interventions & Clinical Trials

Dr. Francis Mhimbira is an epidemiologist and a research scientist based at Ifakara Health Institute. Dr. Mhimbira received his medical degree at Muhimbili University College of Health Sciences (MUCHS), Tanzania, and did a Masters degree in Epidemiology from The University of Melbourne, Australia. He works within the intervention thematic group and conducts research on TB clinical trials for new drugs and vaccines. His work also involves evaluating new TB diagnostic tools and epidemiological studies on TB and co-infections (such as HIV, helminth and respiratory pathogens). Francis also does operational research to improve TB case detection and improve TB treatment outcomes. He is currently a national and principal investigator of Phase III clinical trial (NC-006) of new TB drugs and regimen. Francis is currently the Head of Interventions and Clinical Trials Department.

View Dr. Mhimbira’s Research Interests and Publications

Projects

Evaluation of combinations of bedaquiline, moxifloxacin, PA‐824 and pyrazinamide for treatment of newly-diagnosed TB patients

Evaluation of efficacy, safety and tolerability of a three-drug regimen (Moxifloxacin+PA‐824+Pyrazinamide) for TB and MDR-TB

A PIXELBASE DESIGN
© Ifakara Health Institute (IHI), 2016